European Internal Neurostimulation Market: JSBMarketResearch
The European internal neurostimulation devices market is mainly driven by rapidly aging population and associated diseases like Alzheimer’s, epilepsy, spinal cord injury, and Parkinson’s disease. The European internal neurostimulation market was $947.8 million in 2013, and is expected to reach $1715.8 million by 2018 at a CAGR of 13.0%. The internal neuromodulation market was the largest segment constituting 87% of the overall neurostimulation market.
The report ‘The European Internal Neurostimulation Devices Market forecast, 2012-2018’ analyzes internal neurostimulation market segmented by modalities including spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES), and by applications such as chronic pain, failed back surgery syndrome, refractory angina pectoris, peripheral neuropathy, Alzheimer’s, Dystonia, Tourette’s Syndrome, Parkinson’s, epilepsy, fecal incontinence, and urine incontinence and gastroparesis.
These segments experienced a positive growth until 2012, with an increased awareness for procedures and sophisticated diagnostic techniques. With a market value of $2.3 and $0.6 billion, the spinal cord stimulation (SCS) and deep brain stimulation (DBS) segments contributed 51% and 14%, in terms of value, towards the total internal neurostimulation device market. Both the markets have been witnessing high growth because of the increase in patient pool and procedure numbers of the various modalities.
Procedure volume growth is significantly higher in BIC (Brazil, India, China) and Mexico because of fast disease progression, higher prevalence, improving healthcare infrastructure, economic growth, broadening insurance coverage, expanding private healthcare sector, and increasing awareness amongst people.
The prevalence of Alzheimer’s in North America and Europe is around 5.4-6.4% in adult population whereas in Asia, it is around 4%. The incidences of Alzheimer’s were 411,000 in 2000. This number increased to 454,000 in 2010, and is expected to reach 615,000 by 2030 and 959,000 by 2050. Such high incidence rates in neurological disorders will positively affect the market for neuromodulation.
The report also provides an extensive competitive landscaping of companies operating in the European internal neurostimulation market. Major players dominating the European internal neurostimulation market include Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), and Neuronetics, Inc. (U.S.) Emerging players in this market include Biocontrol Medical, ANM Neuromodulation GmbH, and Magstim Company Limited.
Segment and country-specific company shares, news & deals, mergers and acquisitions, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.
Customization Options
Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:
Product Analysis
Usage pattern (in-depth trend analysis) of products (segment wise)
Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment level
End-user adoption rate analysis of the products (segment wise and country wise)
Comprehensive coverage of product approvals, pipeline products, and product recalls
Epidemiology Data
Country-specific prevalence of Alzheimer’s ,Parkinson’s, epilepsy and stroke
Country-specific incidence of Alzheimer’s, Parkinson’s, epilepsy, stroke
Country-specific mortality rate of stroke and epilepsy
Country-specific patient pool of Alzheimer’s, Parkinson’s, epilepsy and stroke
Disease progression (pattern analysis)
For more information on this report visit –
Procedure Volume Data
Country-wise number of surgeries for epilepsy, heart failure, Alzheimer’s, and Parkinson’s
Surgeons/Physicians Perception analysis
Fast turn-around analysis of surgeons’ response to market events and trends
Pattern analysis of usage of spinal cord stimulation (SCS) and deep brain stimulation (DBS) by physicians
Surgeons’ opinion about products from different companies
Surgeons’ qualitative inputs on epidemiology data
Brand/Product Perception Matrix
Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Pricing Trends
Cost analysis of the European internal neurostimulation devices
The European internal neurostimulation procedural investment
Competitive Intelligence
The company share analysis for the top players of this market in Europe
The crucial developments and strategies of the companies inculcated in their portfolio of the European internal neurostimulation market
Table of Contents
1 Introduction
1.1 Introduce the Market
1.2 Objective of the study
1.3 Market Definition and Scope of the study
1.3.1 Market Definition
1.3.2 Areas covered
1.3.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Secondary sources
1.5.2 Primary Sources
1.5.3 Market estimation methodology (Top-down, bottom-up, data triangulation.)
1.5.4 Macro indicators for the study
1.6 Assumptions
1.7 List of Acronyms
2 Market Overview
3 Internal Neurostimulation-Europe, By SurgeryProcedures
3.1 Split By Geography
3.2 Internal Neurostimulation-Europe-Direct Nerve Repair
3.2.1 Internal Neurostimulation-Europe-Direct Nerve Repair, By Geographies
3.2.1.1 Internal Neurostimulation-United Kingdom-Direct Nerve Repair
3.2.1.2 Internal Neurostimulation-France-Direct Nerve Repair
3.3 Internal Neurostimulation-Europe-Nerve Grafting
3.3.1 Internal Neurostimulation-Europe-Nerve Grafting, By Geographies
3.3.1.1 Internal Neurostimulation-United Kingdom-Nerve Grafting
3.3.1.2 Internal Neurostimulation-France-Nerve Grafting
3.4 Internal Neurostimulation-Europe-Stem cell therapy
3.4.1 Internal Neurostimulation-Europe-Stem cell therapy, By Geographies
3.4.1.1 Internal Neurostimulation-United Kingdom-Stem cell therapy
4 Internal Neurostimulation-Europe, By Types
4.1 Split By Geography
4.2 Spinal cord stimulator-Europe
4.2.1 Spinal cord stimulator-Europe, By Applications
Post Your Ad Here
Comments